Related Experiment Video

Updated: Jun 23, 2026

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

siRNA delivery systems for cancer treatment

Yu-Kyoung Oh1, Tae Gwan Park

  • 1School of Life Sciences and Biotechnology, Korea University, Seoul, South Korea.

Advanced Drug Delivery Reviews
|May 9, 2009
PubMed

Insights

Small interfering RNAs (siRNAs) show promise for treating cancers, but effective systemic delivery remains a challenge. This review explores various in vivo delivery strategies to overcome these hurdles for novel cancer therapeutics.

Area of Science:

  • Biomedical Science
  • Molecular Medicine
  • Cancer Therapeutics

Background:

  • RNA interference (RNAi) mechanisms are increasingly understood, positioning small interfering RNAs (siRNAs) as novel nucleic acid medicines.
  • While siRNA candidates for ocular and respiratory diseases are in clinical trials, anti-cancer applications face significant delivery challenges, especially for systemic administration.

Purpose of the Study:

  • To review various in vivo delivery strategies for small interfering RNAs (siRNAs).
  • To discuss the progress of siRNA delivery systems specifically for gynecologic, liver, lung, and prostate cancers.

Main Methods:

  • Review of existing literature on siRNA delivery technologies.
  • Analysis of chemical modification, conjugation, lipid-based, polymer-based, and physical delivery methods.
  • Examination of current advancements in siRNA delivery for specific cancer types.

Main Results:

  • Existing technologies for nucleic acid medicine delivery have facilitated progress in in vivo siRNA delivery.
  • Various strategies including chemical modification, lipid-based techniques, polymer-based nanosystems, and physical methods are being explored.
  • Significant progress has been made in developing siRNA delivery systems for gynecologic, liver, lung, and prostate cancers.

Conclusions:

  • Effective in vivo delivery is crucial for advancing siRNA-based cancer therapeutics.
  • Diverse delivery strategies are being developed to address challenges like off-target effects and immune stimulation.
  • Continued research in siRNA delivery systems holds promise for treating various cancers.

More Related Videos

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...